Engineering a Cysteine-Free Form of Human Fibroblast Growth Factor-1 for “Second Generation” Therapeutic Application
- Florida State Univ., Tallahassee, FL (United States)
- Univ. of Kansas, Lawrence, KS (United States)
- Washington Univ. School of Medicine, St. Louis, MO (United States)
Human fibroblast growth factor-1 (FGF-1) has broad therapeutic potential in regenerative medicine but has undesirable biophysical properties of low thermostability and 3 buried cysteine (Cys) residues (at positions 16, 83, and 117) that interact to promote irreversible protein unfolding under oxidizing conditions. Mutational substitution of such Cys residues eliminates reactive buried thiols but cannot be accomplished simultaneously at all 3 positions without also introducing further substantial instability. The mutational introduction of a novel Cys residue (Ala66Cys) that forms a stabilizing disulfide bond (i.e., cystine) with one of the extant Cys residues (Cys83) effectively eliminates one Cys while increasing overall stability. This increase in stability offsets the associated instability of remaining Cys substitution mutations and permits production of a Cys-free form of FGF-1 (Cys16Ser/Ala66Cys/Cys117Ala) with only minor overall instability. The addition of a further stabilizing mutation (Pro134Ala) creates a Cys-free FGF-1 mutant with essentially wild-type biophysical properties. The elimination of buried free thiols in FGF-1 can substantially increase the protein half-life in cell culture. In this work, we show that the effective cell survival/mitogenic functional activity of a fully Cys-free form is also substantially increased and is equivalent to wild-type FGF-1 formulated in the presence of heparin sulfate as a stabilizing agent. The results identify this Cys-free FGF-1 mutant as an advantageous “second generation” form of FGF-1 for therapeutic application.
- Research Organization:
- Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- Trefoil Therapeutics, LLC; Florida State University; National Institutes of Health (NIH)
- Grant/Contract Number:
- HL105732
- OSTI ID:
- 1247356
- Journal Information:
- Journal of Pharmaceutical Sciences, Vol. 105, Issue 4; ISSN 0022-3549
- Publisher:
- ElsevierCopyright Statement
- Country of Publication:
- United States
- Language:
- ENGLISH
Web of Science
Aggrescan3D (A3D) 2.0: prediction and engineering of protein solubility
|
journal | May 2019 |
Unraveling the Connection between Fibroblast Growth Factor and Bone Morphogenetic Protein Signaling
|
journal | October 2018 |
Similar Records
Formation of a Stabilized Cysteine Sulfinic Acid Is Critical for the Mitochondrial Function of the Parkinsonism Protein DJ-1
Selenocysteine Positional Variants Reveal Contributions to Copper Binding From Cysteine Residues in Domains 2 And 3 of Human Copper Chaperone for Superoxide Dismutase